Browsing Tag

BTN3A

ImCheck Presents Initial Patient Data from the EVICTION-2 Clinical Trial at SITC Annual Meeting

Jason Junior Nov 11, 2022

Low-dose ICT01 plus low-dose IL-2 safely and significantly increase the number of activated γ9δ2 T cells, CD8 T cells, and Natural Killer cells in patients with solid tumors Marseille, France, November 11, 2022 – ImCheck Therapeutics…

Health

ImCheck Closes Upsized EUR 96 Million (USD 103 Million) Financing to Advance Clinical Program of…

Jason Junior Jun 13, 2022

Significant round will enable the Company to advance ICT01, its lead anti-butyrophilin 3A antibody, to completion of randomized Phase II trialsSeries C adds global investors Earlybird, Andera Partners, Invus and patient organization The…

Health

ImCheck Provides Promising Updated Patient Response Data from the Phase I/IIa EVICTION Trial with…

Jason Junior Nov 13, 2021

Oral presentation includes positive safety data across a wide range of ICT01 doses and efficacy data from patients receiving ICT01 plus pembrolizumab confirming durable clinical responses at low ICT01 dosesOne patient with…